{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:08Z","timestamp":1791515828622,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:00:51Z","timestamp":1608267651000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials \u2013 A collaborative SIOP-RTSG, COG\u00a0and ITCC session at the first SIOPE meeting"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-0228","authenticated-orcid":false,"given":"Jesper","family":"Brok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies M.C.","family":"Mavinkurve-Groothuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-6179","authenticated-orcid":false,"given":"Jarno","family":"Drost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-2889","authenticated-orcid":false,"given":"Daniela","family":"Perotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-315X","authenticated-orcid":false,"given":"Amy L.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-2792","authenticated-orcid":false,"given":"Claudia","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Verschuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Polanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pritchard-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marry","family":"van den Heuvel-Eibrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.012_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2016.09.005","article-title":"Biology and treatment of renal tumours in childhood","volume":"68","author":"Brok","year":"2016","journal-title":"Eur J Canc"},{"issue":"27","key":"10.1016\/j.ejca.2020.11.012_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2015.62.1888","article-title":"Advances in wilms tumor treatment and biology: progress through international collaboration","volume":"33","author":"Dome","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.012_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/pbc.20822","article-title":"Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D. A report from the National Wilms Tumor Study Group","volume":"48","author":"Green","year":"2007","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.11.012_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pbc.21267","article-title":"Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group","volume":"50","author":"Malogolowkin","year":"2008","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.11.012_bib5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1586\/era.09.159","article-title":"Treatment of relapsed Wilms tumors: lessons learned","volume":"9","author":"Spreafico","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2020.11.012_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejca.2017.04.005","article-title":"Review of phase I and II trials for Wilms' tumour - can we optimise the search for novel agents?","volume":"79","author":"Brok","year":"2017","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.11.012_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/pbc.25357","article-title":"Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG)","volume":"62","author":"Mavinkurve-Groothuis","year":"2015","journal-title":"Pediatr Blood Canc"},{"issue":"2","key":"10.1016\/j.ejca.2020.11.012_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26849","article-title":"Irinotecan for relapsed wilms tumour in paediatric patients: SIOP experience and review of the literature; a report from the SIOP renal tumour study group (RTSG)","volume":"65","author":"Hol","year":"2018","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.11.012_bib9","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2007.10.9298","article-title":"Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study","volume":"25","author":"Metzger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.012_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejca.2012.07.010","article-title":"An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour","volume":"49","author":"Ha","year":"2013","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.ejca.2020.11.012_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41409-019-0661-7","article-title":"High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation","volume":"55","author":"Spreafico","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"51","key":"10.1016\/j.ejca.2020.11.012_bib12","doi-asserted-by":"crossref","first-page":"84736","DOI":"10.18632\/oncotarget.12450","article-title":"A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors","volume":"7","author":"Pearson","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2020.11.012_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178593","article-title":"A phase I study of single-agent perifosine for recurrent of refractory pediatric CNS and solid tumors","volume":"12","author":"Becher","year":"2017","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.ejca.2020.11.012_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1211, a report from the Children's Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr Blood Canc"},{"issue":"11","key":"10.1016\/j.ejca.2020.11.012_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26565","article-title":"A phase 1 study of the c-Met inhibitor, Tivantinib (ARQ197) in children with relapsed or refractory solid tumors: a Children's Oncology group study phase 1 and pilot consortium trial (ADVL1111)","volume":"64","author":"Geller","year":"2017","journal-title":"Pediatr Blood Canc"},{"issue":"5","key":"10.1016\/j.ejca.2020.11.012_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26944","article-title":"Phase 1 trial of ontuxixumab (MORAb-004) in children with relapsed or refractory solid tumors: a report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)","volume":"65","author":"Norris","year":"2017","journal-title":"Pediatr Blood Canc"},{"issue":"23","key":"10.1016\/j.ejca.2020.11.012_bib17","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1002\/cncr.31725","article-title":"A study of Axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: a Children's Oncology group phase 1 and pilot consortium trial (ADVL1315)","volume":"124","author":"Geller","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2020.11.012_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27217","article-title":"A phase \u00bd dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system","volume":"65","author":"Manley","year":"2018","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.11.012_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2018.05.002","article-title":"Phase I results of a phase I\/II study of weekly nab-paclitaxel in paediatric patients with recurrent\/refractory solid tumours: a collaboration with innovative therapies for children with cancer","volume":"100","author":"Moreno","year":"2018","journal-title":"Eur J Canc"},{"issue":"8","key":"10.1016\/j.ejca.2020.11.012_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27066","article-title":"A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase 1 Consortium study (ADVL1314)","volume":"65","author":"Schafer","year":"2018","journal-title":"Pediatr Blood Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1377872","article-title":"Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors","volume":"7","author":"Tsuchiya","year":"2018","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.ejca.2020.11.012_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-018-3634-4","article-title":"A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors","volume":"82","author":"Wood","year":"2018","journal-title":"Canc Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2020.11.012_bib23","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-18-2675","article-title":"A phase II study of alisertib in children with recurrent\/refractory solid tumors or leukemia: children's Oncology group phase I and pilot consortium (ADVL0921)","volume":"25","author":"Moss\u00e9","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.012_bib24","author":"Le Teuff","year":"2019","journal-title":"Pediatr Blood Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Phase 1\/2 KEYNOTE-051 study of pembrolizumab in pediatric patients with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"iMATRIX-Atezolizumab, a safety, and pharmacokinetics and activity study of atezolizumab in pediatric and young adult patients with previously treated solid tumors","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.11.012_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrc3002","article-title":"Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene","volume":"11","author":"Huff","year":"2011","journal-title":"Nat Rev Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.11.012_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cjp2.77","article-title":"TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia","volume":"3","author":"Wegert","year":"2017","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"10.1016\/j.ejca.2020.11.012_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2015.01.003","article-title":"Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors","volume":"27","author":"Walz","year":"2015","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2020.11.012_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ebiom.2016.05.029","article-title":"Intra-tumor genetic heterogeneity in wilms tumor: clonal evolution and clinical implications","volume":"9","author":"Cresswell","year":"2016","journal-title":"EBioMedicine"},{"issue":"30","key":"10.1016\/j.ejca.2020.11.012_bib31","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.18.01972","article-title":"AREN0532 and AREN0533 study committees augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology wilms tumor: a Children's Oncology group AREN0532 and AREN0533 study report","volume":"37","author":"Dix","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2020.11.012_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.21951","article-title":"Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse","volume":"51","author":"Perotti","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"10.1016\/j.ejca.2020.11.012_bib33","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.2015.66.0001","article-title":"Gain of 1q as a prognostic biomarker in wilms tumors (WTs) treated with preoperative chemotherapy in the international society of paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study","volume":"34","author":"Chagtai","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2020.11.012_bib34","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2015.66.1140","article-title":"Association of chromosome 1q gain with inferior survival in favorable-histology wilms tumor: a report from the Children's Oncology group","volume":"34","author":"Gratias","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2020.11.012_bib35","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-16-0985","article-title":"Significance of TP53 mutation in wilms tumors with diffuse anaplasia: a report from the Children's Oncology group","volume":"22","author":"Ooms","year":"2016","journal-title":"Clin Canc Res"},{"issue":"10","key":"10.1016\/j.ejca.2020.11.012_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109924","article-title":"TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia","volume":"9","author":"Maschietto","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2087","article-title":"Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour","volume":"211","author":"Natrajan","year":"2007","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.ejca.2020.11.012_bib38","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.18632\/oncotarget.6950","article-title":"Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences","volume":"7","author":"Spreafico","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ejca.2020.11.012_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ng.3940","article-title":"A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor","volume":"49","author":"Gadd","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ejca.2020.11.012_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11523-017-0507-4","article-title":"Targeting the Wnt pathway in cancer: a review of novel therapeutics","volume":"12","author":"Tabatabai","year":"2017","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ejca.2020.11.012_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4939-6563-2_10","article-title":"Design of multimodal small molecules targeting miRNAs biogenesis: synthesis and in\u00a0vitro evaluation","volume":"1517","author":"Vo","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/jpsu.2001.20000","article-title":"The survivin:fas ratio in pediatric renal tumors","volume":"36","author":"Takamizawa","year":"2001","journal-title":"J Pediatr Surg"},{"issue":"2","key":"10.1016\/j.ejca.2020.11.012_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1097-0215(19990420)84:2<192::AID-IJC17>3.0.CO;2-1","article-title":"Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases","volume":"84","author":"Re","year":"1999","journal-title":"Int J Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/15513815.2016.1256358","article-title":"Role of CD56 in normal kidney development and wilms tumorigenesis","volume":"36","author":"Yap","year":"2017","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.ejca.2020.11.012_bib45","author":"Geller","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2020.11.012_bib46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.18632\/oncotarget.468","article-title":"Stratification of Wilms tumor by genetic and epigenetic analysis","volume":"3","author":"Scott","year":"2012","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.ejca.2020.11.012_bib47","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.ejca.2012.06.008","article-title":"Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients","volume":"48","author":"Segers","year":"2012","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.012_bib48","article-title":"Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses","author":"Brzezinski","year":"2020","journal-title":"Br J Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.11.012_bib49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-019-09822-4","article-title":"Novel therapy for pediatric and adolescent kidney cancer","volume":"38","author":"Walz","year":"2019","journal-title":"Canc Metastasis Rev"},{"issue":"8","key":"10.1016\/j.ejca.2020.11.012_bib50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.26448","article-title":"Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study","volume":"64","author":"Modak","year":"2017","journal-title":"Pediatr Blood Canc"},{"issue":"26","key":"10.1016\/j.ejca.2020.11.012_bib51","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with ex\u00a0vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.11.012_bib52","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mc.22248","article-title":"Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair","volume":"54","author":"Oji","year":"2015","journal-title":"Mol Carcinog"},{"issue":"15","key":"10.1016\/j.ejca.2020.11.012_bib53","article-title":"Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience","volume":"37","author":"Berlanga","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib54","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1038\/s41467-019-13646-9","article-title":"Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor","volume":"10","author":"Murphy","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ejca.2020.11.012_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Canc"},{"issue":"6444","key":"10.1016\/j.ejca.2020.11.012_bib56","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"issue":"6378","key":"10.1016\/j.ejca.2020.11.012_bib57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejca.2020.11.012_bib58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41467-020-15155-6","article-title":"An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity","volume":"11","author":"Calandrini","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ejca.2020.11.012_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrurol.2017.163","article-title":"Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","volume":"14","author":"van den Heuvel-Eibrink","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ejca.2020.11.012_bib60","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pbc.24785","article-title":"Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab","volume":"61","author":"Venkatramani","year":"2014","journal-title":"Pediatr Blood Canc"},{"issue":"14","key":"10.1016\/j.ejca.2020.11.012_bib61","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.01265","article-title":"Activity of vincristine and irinotecan in diffuse anaplastic wilms tumor and therapy outcomes of stage II to IV disease: results of the Children's Oncology group AREN0321 study","volume":"38","author":"Daw","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:28Z","timestamp":1760733028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":61,"alternative-id":["S0959804920313356"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials \u2013 A collaborative SIOP-RTSG, COG\u00a0and ITCC session at the first SIOPE meeting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}